Alan Irvine, principal investigator for our Phase 1b #trial of SYX-5219 in adults with moderate to severe #atopicDermatitis explains what we can learn from the recent positive results #Biotech#Innovation
As #EczemaAwarenessMonth closes, we reflect on the ongoing burden for the >200M people living with atopic dermatitis. Our Phase 1b SYX-5219 data are a step toward therapies beyond symptom control. Read more: sitryx.com/news/sitryx-re…#Sitryx
Our CEO Iain Kilty, CFO Adam Mostafa, and CMO Ravi Rao will be participating in two investor conferences this November. We look forward to seeing you there! Read more: sitryx.com/news/sitryx-to…